Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been given a consensus rating of “Buy” by the sixteen analysts that are currently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $61.92.
A number of analysts have recently weighed in on ESPR shares. Chardan Capital increased their price target on Esperion Therapeutics from $20.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 6th. BidaskClub cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Northland Securities started coverage on Esperion Therapeutics in a research report on Tuesday, August 29th. They set an “outperform” rating and a $72.00 price target on the stock. Jefferies Group reiterated a “buy” rating and set a $85.00 price target on shares of Esperion Therapeutics in a research report on Monday, August 21st. Finally, Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up $0.16 during trading on Friday, hitting $57.13. The stock had a trading volume of 489,723 shares, compared to its average volume of 1,019,511. Esperion Therapeutics has a fifty-two week low of $10.71 and a fifty-two week high of $65.20.
In related news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the sale, the director now directly owns 2,472 shares in the company, valued at approximately $133,117.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 32.50% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of ESPR. Tower Research Capital LLC TRC increased its position in Esperion Therapeutics by 69,371.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 4,856 shares during the period. Aperio Group LLC acquired a new stake in Esperion Therapeutics in the 2nd quarter valued at approximately $249,000. SG Americas Securities LLC increased its position in Esperion Therapeutics by 74.5% in the 2nd quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 2,991 shares during the period. Voya Investment Management LLC increased its position in Esperion Therapeutics by 12.7% in the 2nd quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 806 shares during the period. Finally, Metropolitan Life Insurance Co. NY bought a new position in Esperion Therapeutics during the 1st quarter valued at $385,000. Hedge funds and other institutional investors own 92.28% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Analysts Set Esperion Therapeutics, Inc. (ESPR) Target Price at $61.92” was posted by Week Herald and is the property of of Week Herald. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://weekherald.com/2017/12/27/analysts-set-esperion-therapeutics-inc-espr-target-price-at-61-92.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.